Zai Lab Announces BLA Acceptance for TIVDAK in Cervical Cancer
March 13, 2025
Zai Lab Limited announced that China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment